5th Annual Spring To Life Conference on Hematologic Malignancies
Spring to Life Conference on Hematologic MalignanciesTM: Conference on Indolent Lymphoid Malignancies is an accredited, educational program developed by New York Oncology Hematology (NYOH), in collaboration with the Center for Emergency Medical Education (CEME), the Leukemia & Lymphoma Society, and a panel of expert faculty from the academic, research, and community practice settings.
With programming for both healthcare professionals and the community, the goal of this 1-day activity is to bring together cancer care providers and members of the community, including patients, survivors, their family, and caregivers, to gain an up-to-date understanding of blood cancers, including ongoing
research, clinical management, and emerging therapies. The program also provides perspectives on the impact of cancer on the lives of patients and families. The 2018 conference will focus on indolent lymphoid malignancies. Specifically, clinician sessions will detail standards of care and current evidence-based and emerging therapeutics, including efficacy, safety, and tolerability, in order to inform a clinical audience on the more common indolent lymphomas and chronic lymphocytic leukemia. The theme of the afternoon patient program is Finding Hope in Times of Transition.
Healthcare professionals are welcome and encouraged to participate in the afternoon patient-centered sessions. You will receive additional information about this program after registering for the conference.
The 5th Annual Spring to Life Conference on Hematologic Malignancies™: Conference on Indolent Lymphoid Malignancies is proudly hosted by New York Oncology Hematology, PC
There is no fee for this educational activity
The target audience for this conference is hematologists, oncologists, oncology nurses, family and primary care practitioners, allied health professionals, and any other interested cancer care providers.
The afternoon session is for patients who have been diagnosed with a blood cancer, as well as their families, companions, and caregivers. Healthcare professionals are welcome and encouraged to participate in the afternoon patient-centered sessions.
- Identify immunophenotypic and molecular profiling, relevant signaling pathways, and the role of targeted therapies for indolent lymphomas and chronic lymphocytic leukemia
- Review the current standard of care and therapy options for indolent lymphomas and chronic lymphocytic leukemia
- Evaluate the emerging clinical trial data and immune-oncology approaches to the treatment of indolent lymphomas and chronic lymphocytic leukemia
- Demonstrate the clinical application of this information in the common hematology-oncology practice setting
- 3.75 AMA PRA Category 1 Credits™
- 3.75 Certificate of Participation